Improvement of inflammatory dermatoses severity and quality of life in XXXX treated with a betamethasone valerate plaster (LIBERE study).

@entity1 @entity1899 @entity5935 @entity2026 @entity484
BACKGROUND: A ready to use @entity5935 valerate 0.1% ( @entity1899 ) dressing was effective and well-tolerated by @entity1 receiving chronic plaque psoriasis treatment. OBJECTIVE: Collect data related to @entity1899 dressing used in the context of market authorization. METHODS: An observational, prospective study, including 258 @entity1 with a maximum 4-weeks-treatment of inflammatory dermatosis with @entity1899 2.25   mg plaster was performed. The prescription pattern was described and the disease severity assessed using a @entity2026 ( @entity2026 ). @entity1 satisfaction as well as their quality of life (DLQI) were evaluated. Clinical evaluation was performed before and after the treatment. RESULTS: The DLQI scores improved from 10.0        5.4 to 3.5        3.5 points (p   <   0.0001) and @entity2026 decreased from 12.5        3.1 to 4.2        3.0 points (p   <   0.0001). The highest DLQI and @entity2026 improvement was reported for the @entity484 group. Subjects reported the test dressing was better than prior therapies with 93.5% very satisfied and 90.4% satisfied. CONCLUSIONS: The @entity1899 dressing is well-tolerated and effective in the treatment of inflammatory dermatoses, improving both the objective signs of the disease as well as @entity1 ' quality of life.
